MARTINSRIED and MUNICH, Germany, Dec. 13 /PRNewswire/ -- MorphoSys AG (Neuer Markt: MOR) announced the successful installation of MorphoSys' fully automated antibody generation system AutoCAL(TM) at the DuPont Pharmaceuticals research facility in Wilmington, DE/USA. AutoCAL(TM) is MorphoSys' proprietary robotic system that allows high throughput screening utilizing the HuCAL® antibody libraries. With the completion of a successful AutoCAL(TM) test run, MorphoSys received a milestone payment from DuPont Pharmaceuticals. Financial details were not disclosed.
``This was the first time we installed our robotic system at a partner's site'', said Dr. Thomas von Rueden, Chief Scientific Officer, MorphoSys AG. ``This collaboration proves that the AutoCAL(TM) system is now sufficiently robust to be used outside of our facility.''
MorphoSys develops and applies innovative technologies for the production of synthetic antibodies which accelerate drug discovery and target characterization. Founded in 1992, the Company's proprietary Human Combinatorial Antibody Library (HuCAL®) technology is used by researchers world-wide for human antibody generation. The Company currently has licensing and research collaborations with Bayer (Berkeley, California/USA), Roche AG (Basel/Switzerland), DuPont Pharmaceuticals (Wilmington, Delaware/USA), Millennium (Cambridge, Mass/USA), Chiron (Emeryville, California/USA), GPC Biotech AG (Munich/Germany) ProChon Biotech (Rehovot/Israel), Eos Biotechnology (South San Francisco/California/USA) and ImmunoGen (Cambridge, Mass/USA).... |
